Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025

Reuters

08/01

Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025

Sihuan Pharmaceutical Holdings Group Ltd. has issued a positive profit alert, indicating an optimistic financial outlook for the first half of 2025. The company expects to record a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the period ending June 30, 2025. This growth is attributed to the successful launch of significant new products, including the Insulin Degludec and Insulin Aspart Injection, branded as Huiyoujia®, and the Insulin Degludec Injection, branded as Huiyouda®. These products are anticipated to drive strong momentum for future revenue and profit growth. The detailed financial results will be disclosed in the interim results announcement, expected to be published before the end of August 2025. Shareholders and potential investors are advised to exercise caution as the information has not been audited and may be subject to adjustments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2556581145"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556581145\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556581145?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-01 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556581145","market":"us","top_or_hot":-1,"title":"Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHPHF\">Sihuan Pharmaceutical Holdings Group Ltd.</a> has issued a positive profit alert, indicating an optimistic financial outlook for the first half of 2025. The company expects to record a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the period ending June 30, 2025. This growth is attributed to the successful launch of significant new products, including the Insulin Degludec and Insulin Aspart Injection, branded as Huiyoujia®, and the Insulin Degludec Injection, branded as Huiyouda®. These products are anticipated to drive strong momentum for future revenue and profit growth. The detailed financial results will be disclosed in the interim results announcement, expected to be published before the end of August 2025. Shareholders and potential investors are advised to exercise caution as the information has not been audited and may be subject to adjustments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHPHY\">Sihuan Pharmaceutical Holdings Group Ltd.</a> published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-01 22:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHPHF\">Sihuan Pharmaceutical Holdings Group Ltd.</a> has issued a positive profit alert, indicating an optimistic financial outlook for the first half of 2025. The company expects to record a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the period ending June 30, 2025. This growth is attributed to the successful launch of significant new products, including the Insulin Degludec and Insulin Aspart Injection, branded as Huiyoujia®, and the Insulin Degludec Injection, branded as Huiyouda®. These products are anticipated to drive strong momentum for future revenue and profit growth. The detailed financial results will be disclosed in the interim results announcement, expected to be published before the end of August 2025. Shareholders and potential investors are advised to exercise caution as the information has not been audited and may be subject to adjustments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/SHPHY\">Sihuan Pharmaceutical Holdings Group Ltd.</a> published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四環醫藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nNDL5ZQJh2:1","article_id":"2556581145","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556581145","pubTimestamp":1754056861,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sihuan Pharmaceutical Holdings Group Ltd. has issued a positive profit alert, indicating an optimistic financial outlook for the first half of 2025. The company expects to record a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the period ending June 30, 2025. This growth is attributed to the successful launch of significant new products, including the Insulin Degludec and Insulin Aspart Injection, branded as Huiyoujia, and the Insulin Degludec Injection, branded as Huiyouda. These products are anticipated to drive strong momentum for future revenue and profit growth. The detailed financial results will be disclosed in the interim results announcement, expected to be published before the end of August 2025. Shareholders and potential investors are advised to exercise caution as the information has not been audited and may be subject to adjustments.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"00460":"四环医药"},"translate_title":"四环医药预计2025年上半年营收超11亿元，净利润超5000万元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":0.9},"content_text":"Sihuan Pharmaceutical Projects Revenue of Over RMB1,100 Million and Net Profit Exceeding RMB50 Million for H1 2025\n    \n\nSihuan Pharmaceutical Holdings Group Ltd. has issued a positive profit alert, indicating an optimistic financial outlook for the first half of 2025. The company expects to record a revenue of not less than RMB1,100 million and a net profit of not less than RMB50 million for the period ending June 30, 2025. This growth is attributed to the successful launch of significant new products, including the Insulin Degludec and Insulin Aspart Injection, branded as Huiyoujia®, and the Insulin Degludec Injection, branded as Huiyouda®. These products are anticipated to drive strong momentum for future revenue and profit growth. The detailed financial results will be disclosed in the interim results announcement, expected to be published before the end of August 2025. Shareholders and potential investors are advised to exercise caution as the information has not been audited and may be subject to adjustments.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}